Datapoint: Biogen Inks Deal for Reata Pharmaceuticals

Biogen Inc. during a July 28 conference call said it has inked a $7.3 billion deal to acquire Reata Pharmaceuticals Inc., a drugmaker that focuses on rare diseases. Reata’s lead asset is Skyclarys, the first-ever treatment for Friedreich’s ataxia, a rare, degenerative, inherited disease of the nervous system that impacts patients’ ability to walk. The drug — a possible blockbuster — gained FDA approval in February. While full coverage information is uncertain due to its relative newness, MMIT Analytics estimates about 24% of insured lives have covered or better access to Skyclarys under the pharmacy benefit so far. Evaluate Pharma projects the drug will bring in $23 million in global sales for 2023, growing to $576 million by 2028.

SOURCE: MMIT Analytics, as of 7/31/23, and Evaluate Pharma

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today